Healthcare

Meet your Healthcare Research team

Malin Corporation

3D4 Medical sold at 10% premium

Malin has announced the sale of 3D4 Medical for an estimated €45m/$50m, of which Malin will net cash proceeds of €17m. This sale is evidence of Malin executing on its strategy to realise...

UDG Healthcare plc

In excellent health for 2020

UDG has reported a strong set of FY 2019 results at the top end of EPS guidance, with both Ashfield Communications & Advisory (C&A) and Sharp (c.80% of profits) delivering ahead of...

Amryt Pharma

Aegerion deal unlocks global opportunity

The Aegerion deal is clearly transformational; however, of greater interest, is that value accretion for shareholders is just beginning. The enlarged group has a global platform to...

UDG Healthcare plc

Delivering to plan; building a leading advisory business

UDG Healthcare has committed c.$250m in the last three years in delivering on its strategy to build an advisory business within Ashfield. This now accounts for over 20% of group profit...

Malin Corporation

H1 2019 results: value/price disconnect compelling

The modest 5% reduction in Malin’s IPEV stands in stark contrast to its 52% share price decline year-to-date. The latter is largely driven by overhang concerns due to Woodford IM’s...

Uniphar

High growth play on speciality Pharma and MedTech

Uniphar is a diversified healthcare services business focused on speciality pharma and medical devices. Structural industry growth, proprietary digital platforms and expansion into new...

Malin Corporation

New Chairman appointed

Liam Daniel has been appointed Chairman of Malin with immediate effect. He replaces Ian Curley, whose departure was flagged by Malin at its AGM in May. We view the appointment of Daniel,...

Mainstay Medical

Completes financing; operational runway extended to 2021

Mainstay has completed its equity and debt financing transactions, raising gross proceeds of €16.9m ($18.9m). The company now has sufficient capital to advance its two main strategic...

Malin Corporation

Sharpening the strategic focus

Malin is sharpening its strategic focus. It has simplified its strategy to focus on four priority assets that hold considerable upside, and the leaner structure provides a longer...

Mainstay Medical

ReActiv8-B pivotal trial data transformational catalyst in Q4

Mainstay Medical is a specialist medical device company developing and commercialising ReActiv8, an innovative therapy for chronic lower back pain. Mainstay could be on the cusp of a...